Clinical trial · Interventional
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
NCT01447225CI-TRIAL-00023864completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cabazitaxel | Drug | Cabazitaxel | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| MM-121 | Drug | Seribantumab | ALIAS |
| Pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- MM-121 plus Gemcitabine
- description
- escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
- interventionNames
- Drug: MM-121
- Drug: Gemcitabine
- type
- EXPERIMENTAL
- label
- MM-121 plus Carboplatin
- description
- carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
- interventionNames
- Drug: MM-121
- Drug: Carboplatin
- type
- EXPERIMENTAL
- label
- MM-121 plus Pemetrexed
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced-stage solid tumors * ≥ 18 years of age * Adequate liver and kidney function Exclusion Criteria: * Any other active malignancy * No known HIV, Hepatitis C or B
References
Publications (0)
Data not yet available
No reference posted for this study.